KDR and clear cell renal carcinoma: In a retrospective analysis, 90 patients with mRCC (clear cell renal cell carcinoma 87%, non-clear renal cell carcinoma 12%) after progression during first-line VEGFR-TKI therapy were assigned to the second-line temsirolimus treatment group or everolimus treatment group [49].